Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timed-Sequential Induction in CBF-AML
NCT00428558Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2007
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of daunorubicin, cytarabine in acute myeloid leukemia (AML), sponsored by Assistance publique - Hôpitaux de Paris. Started Jul 2007; status: completed.
02
Drugs
daunorubicincytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00428558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00428558.